Evaluation of Neuroprotective Effect of Minocycline (minocyclin &RD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01297816|
Recruitment Status : Unknown
Verified December 2010 by Shahid Beheshti University of Medical Sciences.
Recruitment status was: Recruiting
First Posted : February 17, 2011
Last Update Posted : February 17, 2011
This process appears as a incredible and progressive event that will not stop till reattachment of RPE and neurosensory retina happened .
Process of degeneration begins from first hours of RD (Retinal Detachment) establishment Neuroprotection of photoreceptor following RD is a novel and debatable discussion encountered in recent years .
How to stop this phenomena and neuroprotective agent role in this issue are a new interest of researcher.
In the study the investigators are planning to perform a clinical trial to demonstrate the minocycline neuroprotective effect in a double blind design as this impact has been implicated previously in a animal study
|Condition or disease||Intervention/treatment||Phase|
|Retinal Detachment||Drug: placebo Drug: Minocycline||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Evaluation of Minocycline Neuro Protective Role in Retinal Detachment Surgery|
|Study Start Date :||December 2010|
|Estimated Primary Completion Date :||December 2010|
|Estimated Study Completion Date :||April 2011|
Placebo Comparator: placebo
100mg,BD, fo three month
|Placebo Comparator: minocyclin||
- BCVA [ Time Frame: changes of BCVA in 3 month ]outcome method of measurement: Snellen chart
- finding of ERG changes [ Time Frame: 3 months ]outcome method of measurement: ERG( testes)
- finding of OCT changes [ Time Frame: 3 months ]outcome method of measurement: OCT
- finding of FAF changes [ Time Frame: 3 months ]outcome method of measurement: FAF( testes)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01297816
|Iran, Islamic Republic of|
|Labbafinejad medical center||Recruiting|
|Tehran, Iran, Islamic Republic of|
|Contact: Mohsen Azarmina, Associate Professor 00982122585952 firstname.lastname@example.org|
|Principal Investigator: Mohsen Azarmina, Associate Professor|